Gene sequence construct for gene therapy of human immunodeficiency virus infection
US-2024352096-A1 · Oct 24, 2024 · US
Broadly neutralizing antibody and uses thereof
US2015361160A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2015361160-A1 |
| Application number | US-201514731621-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jun 5, 2015 |
| Priority date | Jun 11, 2014 |
| Publication date | Dec 17, 2015 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to an exceptionally broad and potent neutralizing antibody which may comprise cross-clade neutralizing coverage of 83% at a median IC 50 of 0.003 μg/ml, compositions containing the same and uses thereof.
First claim
Opening claim text (preview).
What is claimed is: 1 . An isolated fully human anti-HIV-1 monoclonal antibody, designated PGDM 1400, PGDM 1401, PGDM 1402, PGDM 1403, PGDM 1404, PGDM 1405, PGDM 1406, PGDM 1407, PGDM 1408, PGDM 1409, PGDM 1410, PGDM 1411 or PGDM 1412, comprising a heavy chain sequence and a light chain sequence, each corresponding to PGDM 1400, PGDM 1401, PGDM 1402, PGDM 1403, PGDM 1404, PGDM 1405, PGDM 1406, PGDM 1407, PGDM 1408, PGDM 1409, PGDM 1410, PGDM 1411 or PGDM 1412. 2 . The isolated fully human anti-HIV-1 monoclonal antibody of claim 1 , wherein the antibody is PGDM 1400. 3 . A composition comprising the antibody of claim 1 . 4 . A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier. 5 . A method of inhibiting HIV in a host comprising administering to the host an antibody as claimed in claim 1 . 6 . An expression vector that encodes and stably expresses in vivo an antibody comprising each of a heavy chain sequence of PGDM 1400, PGDM 1401, PGDM 1402, PGDM 1403, PGDM 1404, PGDM 1405, PGDM 1406, PGDM 1407, PGDM 1408, PGDM 1409, PGDM 1410, PGDM 1411 or PGDM 1412 and/or a light chain sequence of PGDM 1400, PGDM 1401, PGDM 1402, PGDM 1403, PGDM 1404, PGDM 1405, PGDM 1406, PGDM 1407, PGDM 1408, PGDM 1409, PGDM 1410, PGDM 1411 or PGDM 1412. 7 . The expression vector of claim 6 wherein the vector contains and expresses in vivo an antibody comprising a heavy chain sequence of PGDM 1400 and/or a light chain sequence of PGDM 1400. 8 . A composition comprising the expression vector of claim 6 . 9 . A pharmaceutical composition comprising the expression vector of claim 6 and a pharmaceutically acceptable carrier. 10 . The expression vector of claim 6 wherein the expression vector comprises a viral based vector. 11 . The composition of claim 10 wherein the vector is viral based. 12 . The pharmaceutical composition of claim 9 wherein the vector is viral based. 13 . The vector, composition or pharmaceutical composition of claim 10 , wherein the virus is an adeno-associated virus (AAV). 14 . A method of inhibiting HIV in a host comprising administering to the host the expression vector as claimed in claim 6 under conditions whereby the vector expresses the antibody. 15 . A method of inhibiting HIV in a host comprising administering to the host the expression vector as claimed in claim 7 under conditions whereby the vector expresses the antibody. 16 . A method of inhibiting HIV in a host comprising administering to the host the expression vector as claimed in claim 10 under conditions whereby the vector expresses the antibody. 17 . A method of inhibiting HIV in a host comprising administering to the host the expression vector as claimed in claim 12 under conditions whereby the vector expresses the antibody. 18 . A method of inhibiting HIV in a host comprising administering to the host the expression vector as claimed in claim 13 under conditions whereby the vector expresses the antibody.
Assignees
Inventors
Classifications
- C07K16/1145Primary
Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site · CPC title
Fab or Fab' · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
from primates, e.g. man · CPC title
Complementarity determining region [CDR] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2015361160A1 cover?
- The present invention relates to an exceptionally broad and potent neutralizing antibody which may comprise cross-clade neutralizing coverage of 83% at a median IC 50 of 0.003 μg/ml, compositions containing the same and uses thereof.
- Who is the assignee on this patent?
- Int Aids Vaccine Initiative, Scripps Research Inst, Univ Cornell
- What technology area does this patent fall under?
- Primary CPC classification C07K16/1145. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Dec 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).